Request Demo
Akums introduces Hydroxyurea oral suspension for sickle cell disease
18 Mar 2024
Cell TherapyDrug ApprovalImmunotherapy
Akums’ new medicine will be sold for sickle cell disease treatment. Credit: kikpokemon / Shutterstock.com.
Akumsn company Akums Drugs and Pharmasickle cell diseaseduced Hydroxyurea oral suspension, the country’s first room temperature-stable drug for treating sickle cell disease, according to a LinkedIn post.
The new formulaAkums Drugs and Pharmaceuticalsternative to impHydroxyureas in the country.sickle cell disease
Designed for ease of use across all age groups suffering from sickle cell disease, Hydroxyurea oral suspension will be offered as oral syringes to guarantee precise dosage, enhancing patient compliance and treatment efficacy.
The existing imported Hydroxyurea solution, which requires refsickle cell disease2°Hydroxyureacosts Rs77,000 ($928.9) in the Indian market.
Akums’ novel oral suspHydroxyurea will be available for Rs600, making it highly accessible to patients.
Akumslso:
With FDA greenlight, BMS Breyanzi brings CAR-T cell therapy to CLL and SLL
AstraFDAeca snaps up BMS Breyanzi1.05bn tCAR-T cellre disease pCLLlineSLL
An inherited blood ailment, sickle cell disease changes the red blood cells into a sickle shape, which hampers their ability to transport oxygen across the body effectively.
AstraZeneca aids red Amolytcells to maintain a rounder and larger shape, allowing for improved oxygen delivery throughout the body.
In a media statement posted on LinkedIn, Akums Drugs and Pharmaceuticals said: “In alignment with the objectives outlined in the national sickle cell anaemia mission, as announced by the Honourable Prime Minister Shri Narendra Modi Ji, Akums pledges to provide this medicine to the government at less than 1% of the cost of global brand imported in India, thus embodying the spirit of ‘Make in India’ and fostering widespread benefit to the masses.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.